ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / GRCE
ATHE (45) DWTX (38) SCYX (28) VERU (30) ⌘ Pro Terminal →

Grace Therapeutics Inc. (GRCE) — RQD Stock Rating Cockpit

$1.81 -6.70% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.78

Grace Therapeutics Inc. (GRCE) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $40.8M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on GRCE Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is GRCE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Grace Therapeutics Inc. (NASDAQ: GRCE) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $1.81 (-6.70% 1D, market cap $40.8M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, GRCE ranks #730 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does GRCE compare to ATHE and DWTX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GRCE carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -18.9%. By comparison, ATHE (Alterity Therapeutics Limited) holds a D grade (45/100 RQD, P/E N/A, ROIC —, cap $39.3M) and DWTX (Dogwood Therapeutics Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -32.3%, cap $43.5M). Among the 5-stock peer group, GRCE leads on earnings multiple (N/A) while GRCE leads on capital efficiency (-18.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for GRCE?
▼

Per GRCE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0001444192), Grace Therapeutics Inc. generated $31.0M in revenue (-33.6% YoY), -$7.8M in net income, and -$8.9M in free cash flow against $68.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.78 (-1.40%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.2% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510032
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D-
Cash (8)Whales (5)SEC (10)Macro (6)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-11.6% Base Target
$5 Bull$2 Base$1 Bear
📬 FREE GRCE RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GRCE)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (32/100 Composite)
🔍 WHY GRCE SCORES 32/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (31% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (25% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
40
Grade D$1.99-0.5% Next Q
Q2 (-2Q)
37
Grade E$1.98-5.6% Next Q
Q3 (-1Q)
35
Grade E$1.87-3.2% Next Q
Current
32
Grade E$1.81-9.2% Hist 90D α
Trajectory: D (40) → E (32)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a GRCE Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While GRCE currently carries a cautious 32/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.06) and Max Pain ($1.90) forces dealer call-delta covering toward $5.44.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $GRCE• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “GRCE Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”
YES 32%NO 68%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
46.230 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
2 / 99-Pt Accounting
52-WEEK LASER RANGE4% OF RANGE
L: $2$1.81H: $5
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 8 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 8 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 16 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

3-of-3 Quant Analysts Bearish Warning on GRCE

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (40)

-18.9% ROIC with 42.0% gross margin and -21.73% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (50)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (23)

8/40 institutional & smart-money positioning score with 6/20 macro alignment.

Bull Case: Why Buyers Like GRCE
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring GRCE)

  • ✓Walkthrough of GRCE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
GRCE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -23.31%▼ DESCENDING CHANNEL
2026-11-03O $1.94H $1.94L $1.81C $1.81VOL 85.9K
RES: $2.33SUP: $1.63SMA50: $2.06SMA200: $2.80
$4.07$3.42$2.77$2.12$1.47RES $2.33SUP $1.63$1.812026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

GRCE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 GRCE Butterfly Map → + Track GRCE →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -33.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on GRCE today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for GRCE. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for GRCE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GRCE)

Health Care Rank #730 of 1015 ⚔️ ATHE vs GRCE Full Matrix →

1. Head-to-Head Health Care Peer Comparison (GRCE vs. ATHE, DWTX, SCYX, VERU)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Grace Therapeutics Inc. (GRCE) ranks #730 by composite RQD confidence (32/100, grade E) and #767 by equity capitalization ($40.8M). Within this direct 5-issuer industry benchmark cohort, GRCE leads on earnings valuation at N/A trailing P/E, while GRCE leads on capital efficiency and profitability with -18.9% ROIC and — gross margin. ATHE currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with GRCE at 32/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
GRCE ACTIVE
Grace Therapeutics Inc.
E 32/100 — — -18.9% -6.70% $40.8M Benchmark Subject
ATHE
Alterity Therapeutics Limited
D 45/100 — — — -3.24% $39.3M /athe-vs-grce →
DWTX
Dogwood Therapeutics Inc.
D- 38/100 — — -32.3% -4.69% $43.5M /dwtx-vs-grce →
SCYX
SCYNEXIS Inc.
E 28/100 — — -35.0% +1.06% $37.5M /scyx-vs-grce →
VERU
Veru Inc.
E 30/100 — — -35.0% -1.37% $37.3M /veru-vs-grce →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-03-31 • CIK 0001444192 ↗

In its most recent audited fiscal period (FY2025, filed 2026-03-31), Grace Therapeutics Inc. (GRCE) reported GAAP revenue of $31.0M (-33.6% vs. FY2024 revenue of $46.7M , and -13.8% cumulative change since FY2023) , GAAP net income of -$7.8M, operating cash flow of -$8.9M, and free cash flow of -$8.9M (+40.5% YoY). On the balance sheet, GRCE closed FY2025 with $68.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2026-03-31 $31.0M -$7.8M -$8.9M -$8.9M $68.5M —
FY2024 (FY) 2025-03-31 $46.7M -$9.6M -$14.9M -$14.9M $61.2M —
FY2023 (FY) 2024-03-31 $36.0M -$12.9M -$12.3M -$12.3M — —

3. GRCE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is GRCE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Grace Therapeutics Inc. (NASDAQ: GRCE) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $1.81 (-6.70% 1D, market cap $40.8M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, GRCE ranks #730 in composite RQD confidence.

How does GRCE compare to ATHE and DWTX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GRCE carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -18.9%. By comparison, ATHE (Alterity Therapeutics Limited) holds a D grade (45/100 RQD, P/E N/A, ROIC —, cap $39.3M) and DWTX (Dogwood Therapeutics Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -32.3%, cap $43.5M). Among the 5-stock peer group, GRCE leads on earnings multiple (N/A) while GRCE leads on capital efficiency (-18.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for GRCE?

Per GRCE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0001444192), Grace Therapeutics Inc. generated $31.0M in revenue (-33.6% YoY), -$7.8M in net income, and -$8.9M in free cash flow against $68.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is GRCE trading relative to its 50-day, 200-day, and 52-week technical levels?

GRCE last traded at $1.81 (-6.70% on volume of 99,541 shares), positioning the stock -12.14% below its 50-day simple moving average ($2.06) and -35.36% below its 200-day simple moving average ($2.80). Across its 52-week range of $1.67 to $5.18, GRCE sits at the 4.0% percentile with a 14-day RSI of 46.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.58 to $2.04).

Direct Sub-Reports: GRCE RQD Cockpit GRCE 12M Forecast GRCE Earnings & Move GRCE Dividends & DRIP GRCE Insiders & 13F GRCE Whale Options GRCE Profit Sankey GRCE News & Why
ROARABLE RATING BRIEF • RQD 32/100 (E) ✓ SEC XBRL & RQD VERIFIED

GRCE — Grace Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-03-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Grace Therapeutics Inc. (GRCE) earns a live Roarable RQD composite score of 32/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.81 (-6.70% 1D, market capitalization $40.8M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -18.9%, gross margin of —, operating margin of —, and free cash flow yield of -21.73%.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Grace Therapeutics Inc. (GRCE) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry..0B on a rounded basis. Revenue is reported as — across the FY 2023 through FY 2025 periods in the SEC financials, indicating no reported revenue in those periods.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2026-03-31), Grace Therapeutics Inc. (GRCE) reported $31.0M in annual revenue (up from $46.7M in FY2024, -33.6% YoY) and -$7.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($36.0M revenue, -$12.9M net income) through FY2025, GRCE scaled operating cash flow to -$8.9M and free cash flow to -$8.9M, backed by $68.5M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 32/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -21.73% and institutional whale pillar of 5/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $1.67 – $5.18 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Sector correlations beyond the stated beta of 1. Second-order bottlenecks cannot be identified from the provided sources. A prospective investor should monitor whether future filings disclose supplier, partner, or licensing relationships that the current graph does not capture.

  • Key Question #1: Can GRCE sustain or expand its — operating margin and -18.9% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $31.0M and free cash flow of -$8.9M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is GRCE's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

GRCE Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Grace Therapeutics Inc. (GRCE) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to GRCE Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

GRCE Bull vs. Bear Conversation Board — What's Your Call at $1.81?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON GRCE 🐻 33% BEARISH CONVICTION
1. Pick Your Side on GRCE:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH 🎯 Target: $2.46 (+26.8%)
📌 Pinned Debate

Cash rose to $18.7M in FY 2025 from $11.1M in FY 2024 while operating loss narrowed, and multiple Opaleye-related purchases appear in t

Cash rose to $18.7M in FY 2025 from $11.1M in FY 2024 while operating loss narrowed, and multiple Opaleye-related purchases appear in the news wire.. When you look under the hood at GRCE, Fundamental Cash Engine is 8/20 with 0.0% gross margins and -18.9% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (5/20) has been quietly accumulating below $5.18. My 12M target is $2.46.

VolSurface_Trader 🐂 BULL

Both sides have a point here — GRCE's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $1.59 (-18.0%)
Spot @ $1.94

ROIC of -18.9%, FCF yield of -21.73%, and zero reported revenue leave the business consuming cash with a Piotroski F of 2 out of 9.

Here is the bear case nobody on the bull side wants to address on GRCE: ROIC of -18.9%, FCF yield of -21.73%, and zero reported revenue leave the business consuming cash with a Piotroski F of 2 out of 9.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.

LIVE TAPE